NEW YORK, June 2, 2026, 17:05 (EDT)
- DiaMedica was last at $5.77, slipping 6 cents from its previous close.
- The company is set to speak at Jefferies’ healthcare conference on June 4.
- Enrollment in its ReMEDy2 stroke trial has now topped 75% of the number needed for the interim analysis.
DiaMedica Therapeutics Inc. shares fell Tuesday, with the drug developer closing lower as the major indexes gained. The stock was last at $5.77 after hours, off 6 cents from its close. It traded between $6.29 and $5.56 earlier in the session. Volume reached about 152,000 shares. Market cap was roughly $311 million.
DiaMedica is heading into a catalyst week as it prepares to present at 3:45 p.m. ET Thursday during the Jefferies Global Healthcare Conference in New York. The event, which runs June 2-4, draws attention from healthcare investors looking for pipeline news and signs of financing.
Trial timing is often more important than immediate earnings for clinical-stage companies, which haven’t brought any drugs to market yet. DiaMedica’s main program, DM199, targets acute ischemic stroke, preeclampsia and fetal growth restriction.
ReMEDy2 is the main asset for now, a Phase 2/3 trial meant to test both safety and efficacy. On May 20, DiaMedica said enrollment in the study had hit 75% of its 200-patient goal, the point needed to trigger a planned interim analysis—a look at how the trial is shaping up before it finishes. Chief Medical Officer Dr. Julie Krop called it “a meaningful milestone” and said the review will be “an important inflection point” for DM199. DiaMedica Therapeutics, Inc.
DiaMedica says acute ischemic stroke happens when a clot blocks blood going to the brain. The company’s DM199 drug is a lab-made version of human tissue kallikrein-1, involved in blood flow regulation. DiaMedica argues approved stroke treatments now are limited by tight time windows and need for specialized access.
Genentech, a Roche unit, said last year its TNKase and Activase drugs are the only FDA-approved options for acute ischemic stroke. Both are thrombolytics, medicines that break up clots. So DiaMedica faces an emergency-care market with established drugs in place as it looks to find space.
Biotech underperformed the wider market. The SPDR S&P Biotech ETF slid $5.83 to $127.76. The iShares Nasdaq Biotechnology ETF lost $5.16 and ended at $164.27.
DiaMedica didn’t get much support from the broader market, though stocks were mostly higher. The Dow was up 0.45%, the S&P 500 gained 0.13% and the Nasdaq Composite edged 0.03% higher. Gains in AI-related stocks helped offset investor caution over geopolitics.
DiaMedica finished March with $51.3 million in cash, cash equivalents and marketable securities, sliding from $59.9 million at the end of last year. First-quarter R&D spending jumped to $8.0 million from $5.7 million a year ago as ReMEDy2 moved to more global sites, according to its latest quarterly filing.
The path isn’t fixed. An interim review could mean a bigger trial, a hold, or a stop for futility, all shifting the financing and valuation for a business with no product sales. More patients may drain cash for longer, even if the program keeps going.
Nasdaq trades from 9:30 a.m. to 4 p.m. Eastern, then after-hours trading goes until 8 p.m. DiaMedica’s newest quoted trade posted outside regular hours.
